Treatment of hypercalcemia associated with malignancy.
D002116:Calcitonin / Q000627:therapeutic use; D002319:Cardiovascular System / Q000503:physiopathology; D004064:Digestive System / Q000503:physiopathology; D004232:Diuretics / Q000627:therapeutic use; D004630:Emergencies; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000503:physiopathology; D009461:Neurologic Manifestations; D010281:Parathyroid Hormone / Q000502:physiology; D010710:Phosphates / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use; D012964:Sodium / Q000627:therapeutic use; D012965:Sodium Chloride / Q000627:therapeutic use; D013431:Sulfates / Q000627:therapeutic use
D004232:Diuretics; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D010710:Phosphates; D013431:Sulfates; D012965:Sodium Chloride; D002116:Calcitonin; D012964:Sodium; D008926:Plicamycin